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Glucose also contributes to lipid oxidation and promotes pathologic changes in membrane structural organiza-
tion, including the development of cholesterol crystalline domains. In this study, we tested the comparative ef-
fects of eicosapentaenoic acid (EPA), an omega-3 fatty acid indicated for the treatment of very high
triglyceride (TG) levels, and other TG-lowering agents (fenoﬁbrate, niacin, and gemﬁbrozil) on lipid oxidation
in human low-density lipoprotein (LDL) as well as membrane lipid vesicles prepared in the presence of
glucose (200 mg/dL). We also examined the antioxidant effects of EPA in combination with atorvastatin o-
hydroxy (active) metabolite (ATM). Glucose-induced changes in membrane structural organization were mea-
sured using small angle x-ray scattering approaches and correlated with changes in lipid hydroperoxide
(LOOH) levels. EPA was found to inhibit LDL oxidation in a dose-dependent manner (1.0–10.0 µM) and was dis-
tinguished from the other TG-lowering agents, which had no signiﬁcant effect as compared to vehicle treatment
alone. Similar effects were observed in membrane lipid vesicles exposed to hyperglycemic conditions. The anti-
oxidant activity of EPA, as observed in glucose-treated vesicles, was signiﬁcantly enhanced in combination with
ATM. Glucose treatment produced highly-ordered, membrane-restricted, cholesterol crystalline domains,
which correlated with increased LOOH levels. Of the agents tested in this study, only EPA inhibited glucose-
induced cholesterol domain formation. These data demonstrate that EPA, at pharmacologic levels, inhibits
hyperglycemia-induced changes in membrane lipid structural organization through a potent antioxidant
mechanism associated with its distinct, physicochemical interactions with the membrane bilayer.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY NC ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
At elevated levels, the aldose sugar glucose produces non-enzymatic
chemical modiﬁcations to membrane proteins and phospholipids,
leading to advanced glycation endproducts (AGEs) and cell injury [1].
Oxidative stress and AGEs have been implicated in both microvascular
and macrovascular complications of diabetes and other metabolic
disorders [1,2]. In membranes enriched with polyunsaturated fatty
acids (PUFAs), hyperglycemia promotes the formation of free radicals
and cholesterol crystalline domains associated with atherosclerosis
[3–6]. The non-enzymatic effects of glucose on cholesterol crystalline
domain formation were shown to be enhanced under conditions of
high cholesterol and could not be reproduced bymannitol [3]. Oxidative
damage to PUFAs with glucose is of particular interest given its role in
the propagation of free radicals during vascular injury and insulin
resistance [1,7,8]. In addition to cell membrane-mediated effects,Box 7100, Beverly, MA 01915-
.
ason).
. This is an open access article underoxidation of PUFAs in low-density lipoprotein (LDL) contributes to en-
dothelial dysfunction, inﬂammation, and atherosclerotic foam cell for-
mation [9,10].
Available clinical evidence indicates that consumption of long-chain,
omega-3 fatty acids correlateswith reduced risk for cardiovascularmor-
tality and morbidity [11,12]. By incorporating into cellular membranes
associatedwith the atherosclerotic plaque, omega-3 fatty acids interfere
with various signal transduction pathways linked to inﬂammation and
endothelial dysfunction during atherogenesis [12,13]. Eicosapentaenoic
acid (EPA; 20:5, n-3) is an omega-3 fatty acid indicated for the treat-
ment of very high triglyceride levels. In the Japan EPA Lipid Intervention
Study (JELIS), highly-concentrated, puriﬁed EPA was effective in
preventing coronary artery disease (CAD) in hypercholesterolemic pa-
tients also receiving statin treatment [14]. In other clinical studies, treat-
ment with puriﬁed EPA slowed atherosclerotic disease progression in
patients with type 2 diabetes and documented CAD [15–17]. Puriﬁed
EPA treatment has also been reported to reduce levels of triglycerides,
high-sensitivity C-reactive protein (hsCRP), lipoprotein-associated
phospholipase A2 (Lp-PLA2), arachidonic acid/EPA (AA/EPA) ratio, and
oxidized LDL levels as compared to placebo [18–23]. This is in contrastthe CC BY NC ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. Effects of EPA on human LDL oxidation examined (A) at various doses and (B) in
comparison to fenoﬁbrate (Fenoﬁb), nicotinic acid (Niacin), and gemﬁbrozil (Gemﬁb),
each at 10.0 μM. Samples were prepared at 100 μg/mL LDL (based on apoB100 content)
and incubated with test agents (at doses indicated) for 30 min prior to initiating lipid ox-
idation using 10 μMCuSO4. Samples weremaintained at 37 °C in a shakingwater bath for
1 hr. Lipid oxidation was measured by colorimetric assay of TBARS formation and
expressed as molar equivalents of malondialdehyde (MDA). Values are mean ± S.D.
(N = 3). **p b 0.001 versus vehicle-treated control; †p b 0.001 versus 1.0 μM
EPA; §p b 0.001 versus 2.5 μM EPA; ¶p b 0.001 versus all other TG-lowering agents
(Student–Newman–Keuls multiple comparisons test; overall ANOVA—panel
A: p b 0.0001, F = 298.14; panel B: p b 0.0001, F = 132.37).
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and niacin, which failed to reduce cardiovascular events as compared to
statin treatment alone (HPS2-THRIVE, FIRST, ACCORD, AIM-HIGH,
FIELD) [24–28]. The basis for these differencesmay be, in part, the result
of direct effects of EPA on plaque formation and stability due to its dis-
tinct physicochemical properties. In particular, its lipophilic structure
andmolecular space dimensions allowEPA to insert efﬁciently into lipo-
protein particles and cell lipid membranes as compared to other TG-
lowering agents.
In this study, we used small angle x-ray scattering (SAXS) to exam-
ine the ability of EPA to interfere with the effects of high glucose on
membrane lipid peroxidation and structural organization in vesicles
enriched in PUFAs. Pronounced changes in membrane lipid organiza-
tionwere observedwith hyperglycemia, including the formation of cho-
lesterol crystalline domains, which correlated with increased formation
of lipid hydroperoxide (LOOH), an intermediate product of oxidative
lipid damage. Treatment with EPA, but not vitamin E or other TG-
lowering agents (fenoﬁbrate, niacin, and gemﬁbrozil), inhibited chang-
es in membrane structural organization due to its potent, chain-
breaking antioxidant actions. EPA also inhibited human LDL oxidation
in amanner distinct from the other TG-lowering agents. Themembrane
antioxidant effects of EPA were enhanced in combination with atorva-
statin o-hydroxy (active) metabolite (ATM).
2. Materials and methods
2.1. Materials
1,2-Dilinoleoyl-sn-glycero-3-phosphocholine [18:2 (Cis) PC or DLPC]
and monomeric cholesterol (isolated from ovine wool) were purchased
from Avanti Polar Lipids (Alabaster, AL) and solubilized at 25 and
10 mg/mL, respectively. EPA was purchased from Sigma-Aldrich (Saint
Louis, MO) and solubilized in ethanol to 1 mM under nitrogen atmo-
sphere. Vitamin E (α-tocopherol) was also purchased from Sigma-
Aldrich and prepared in ethanol at 1.0 mM (ε= 3.06 × 104 M−1 cm−1
at 294 nm) just prior to experimental use. Atorvastatin ortho- (o-) hy-
droxy (active) metabolite was purchased from Toronto Research
Chemicals (North York, Ontario, Canada) and solubilized in methanol
to 1.0mM. Fenoﬁbrate, nicotinic acid (niacin), and gemﬁbrozil were pur-
chased from Sigma-Aldrich and solubilized in ethanol to 1.0 mM. All test
compoundswere further diluted in ethanol or aqueous buffer as needed.
Glucose was prepared in saline buffer (0.5 mM HEPES, 154 mM NaCl,
pH 7.3) at 11.0 mM (200 mg/dL).
CHOD-iodide color reagent (stock) was prepared, with slight modi-
ﬁcation, as described by from El-Saadani et al. [29] and consisted of 0.2
MK2HPO4, 0.12MKI, 0.15mMNaN3, 10 μMammoniummolybdate, and
0.1 g/L benzalkonium chloride. Prior to experimental use, the CHOD re-
agent was activated by adding 24 μM ethylenediaminetetraacetic acid
(EDTA), 20 μMbutylated hydroxytoluene (BHT), and 0.2% Triton X-100.
2.2. LDL isolation and oxidation
LDL was isolated from the plasma of healthy volunteers by density
gradient ultracentrifugation and adjusted to a ﬁnal apolipoprotein
(apoB100) concentration of 10 mg/mL. Samples were prepared at
100 μg/mL apoB100 and incubated with test agents for 30 min at
37 °C in a shaking water bath. Oxidation was initiated by adding 10 μM
CuSO4. After 1 hr, 100 μL aliquots were removed from each sample and
combined with 1.0 mL thiobarbituric acid (0.5%), 10 μL trichloroacetic
acid (10%), 10 μL BHT (35 mM in methanol), and 10 μL EDTA (5 mM).
Sample aliquots were incubated at 100 °C for 30 min and then assayed
for the formation of thiobarbituric acid-reactive substances (TBARS),
which have a molar absorptivity (ε) value of 1.56 × 105 M−1 cm−1 at
532 nm and are derived principally from the reaction of thiobarbituric
acid with malondialdehyde (MDA), a reactive aldehyde produced byLDL oxidation [30,31]. Sample TBARS concentrations were determined
spectrophotometrically and expressed as molar equivalents of MDA.
2.3. Preparation of membrane lipid vesicles
Multilamellar vesicles (MLVs) were prepared as binary mixtures of
DLPC (1.0 or 2.5 mg total phospholipid per sample) and cholesterol at
a ﬁxed cholesterol-to-phospholipid (C/P) mole ratio of 0.6:1. Compo-
nent lipids (in chloroform) were transferred to 13 × 100 mm borosili-
cate culture tubes and combined with vehicle (ethanol) or an equal
volume of omega-3 fatty acid, vitamin E, or ATM stock solution, each ad-
justed to achieve desired treatment concentrations. Sampleswere shell-
dried under nitrogen gas and placed under vacuum for 1 h to remove re-
sidual solvent. After desiccation, each sample was resuspended in
1.0 mL glucose-containing saline to yield ﬁnal phospholipid concentra-
tions of 1.0 or 2.5 mg/mL (for lipid peroxidation or x-ray diffraction
analysis, respectively). Lipid suspensions were then vortexed for
3 min at ambient temperature to form MLVs [32].
2.4. Lipid peroxidation analysis
All MLV samples were subjected to time-dependent autoxidation by
incubating at 37 °C in an uncovered, shaking water bath. This method
allows lipid peroxidation to occur gradually without requiring the use
of exogenous initiators. Small aliquots (5–100 μL) of each sample were
removed, immediately following MLV preparation (0 hr) and after ex-
posing samples to oxidative conditions for 72 or 96 hr, and combined
with 1.0 mL of activated CHOD-iodide color reagent. Aliquot volume
Fig. 3. Separate and combined effects of EPA and atorvastatin o-hydroxy (active)
metabolite (ATM) on glucose-induced membrane lipid peroxidation. Samples were
prepared as previously described and tested for LOOH formation following exposure to
oxidative conditions for 96 hr. Values are mean± S.D. (N= 6) and represent % difference
between treatment and glucose-treated controls. *p b 0.001 versus glucose-treated
control (Student–Newman–Keuls multiple comparisons test; overall ANOVA:
p b 0.0001, F = 111.69). §p b 0.001 versus separate EPA or ATM treatments (Student–
Newman–Keuls multiple comparisons test; overall ANOVA: p b 0.0001, F = 26.635).
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tometric readings were within the optimal absorbance range. Test sam-
pleswere covered and incubated in darkness at room temperature for at
least 4 hr. Sample absorbances were then measured against a CHOD
blank at 365 nm using a Beckman DU-640 spectrophotometer. The
CHOD colorimetric assay is based on the oxidation of iodide (I–) by
lipid hydroperoxide (LOOH) to form triiodide (I3–), the quantity of
which is directly proportional to the amount of LOOH present in the
lipid sample. The molar absorptivity (ε) of I3– is 2.46 × 104 M−1 cm−1
at 365 nm [32].
2.5. X-ray diffraction analysis
The membrane structural effects of glucose and the various com-
pounds examined in this studyweremeasured at 0, 72, and 96 hr inter-
vals. Membrane lipid vesicles were oriented for x-ray diffraction
analysis as described previously [33]. Brieﬂy, a 100 μL aliquot (contain-
ing 250 μg MLV) was aspirated from each sample and transferred to a
Lucite® sedimentation cell ﬁtted with an aluminum foil substrate
upon which a given sample could be collected by centrifugation. Sam-
ples were then loaded into a Sorvall AH-629 swinging bucket rotor
(DuPont Corp., Wilmington, DE) and centrifuged at 35,000 g, 5 °C, for
90 min.
After centrifugal orientation, sample supernatants were aspirated,
and aluminum foil substrates, each supporting a single membrane pel-
let, were removed from the sedimentation cells. Sample pellets were
dried for 5–10 min at ambient conditions, mounted onto curved glass
supports, and placed in hermetically-sealed, brass or glass containersFig. 2. (A) Effect of glucose on membrane lipid peroxidation. Model membranes were
reconstituted from DLPC and cholesterol at a C/P mole ratio of 0.6:1 and prepared in the
absence or presence of glucose (200 mg/dL). Values are mean ± S.D. (N = 6).
**p b 0.001 versus vehicle-treated control (unpaired, two-tailed Student's t-test).
(B) Comparative effects of vitamin E and EPA (each at 1:30 drug-to-phospholipid
mole ratio) on glucose-induced membrane lipid peroxidation. Values are mean ± S.D.
(N = 3). †p b 0.05 and ‡p b 0.001 versus glucose treatment alone; §p b 0.05 and
§§p b 0.001 versus vitamin E treatment (Student–Newman–Keuls multiple comparisons
test; overall ANOVA—0 hr data: p = 0.0073, F = 12.474; 72 hr data: p = 0.0204, F =
7.986; 96 hr data: p= 0.0008, F = 29.764).(for immediate analysis or temporary storage, respectively). All x-ray
diffraction experimentswere conducted at 20 °C, 74% relative humidity.
The latter was established by exposingmembrane samples to saturated
solutions of L-(+) tartaric acid (K2C4H4O6 · ½H2O). Samples were incu-
bated at these conditions for at least 1 hr prior to experimental analysis.
Orientedmembrane sampleswere aligned at grazing incidencewith
respect to a collimated, monochromatic CuKα x-ray beam (Kα1 and Kα2
unresolved; λ= 1.54 Å) produced by a Rigaku Rotaﬂex RU-200, high-Fig. 4. Effects of EPA on glucose-induced membrane lipid peroxidation examined (A) at
various doses and (B) in comparison to Fenoﬁb, Niacin, and Gemﬁb, each at 10.0 μM.
Model membrane samples were reconstituted from DLPC and cholesterol at a C/P mole
ratio of 0.6:1, treatedwith glucose (200 mg/dL), and tested for LOOH formation following
exposure to oxidative conditions for 48 hr. Values are mean ± S.D. (N = 6). **p b 0.001
versus vehicle-treated control; †p b 0.001 versus 1.0 μM EPA; §p b 0.001 versus 2.5 μM
EPA; ¶p b 0.05 versus 5.0 μM EPA; ♦p b 0.001 versus all other TG-lowering agents
(Student–Newman–Keuls multiple comparisons test; overall ANOVA—panel A:
p b 0.0001, F = 561.62; panel B: p b 0.0001, F = 9.940).
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previously described [34]. Diffraction data were collected on a one-
dimensional, position-sensitive electron detector (Hecus X-ray Systems,
Graz, Austria) at a sample-to-detector distance of 150mm. Detector cal-
ibration was performed by themanufacturer and veriﬁed using crystal-
line cholesterol monohydrate.
This technique allows for precise measurement of the unit cell peri-
odicity, or d-space, of the membrane lipid bilayer, which is the distance
from the center of one lipid bilayer to the next, including surface hydra-
tion. The d-space for any given membrane multibilayer is calculated
from Bragg's Law, h λ= 2 d sin θ, where h is the diffraction order, λ is
the wavelength of the x-ray radiation (1.54 Å), d is the membrane
lipid bilayer unit cell periodicity, and θ is the Bragg angle equal to one-
half the angle between the incident beam and scattered beam.
The presence of cholesterol domains in a given membrane sample
results in the production of distinct Bragg (diffraction) peaks having sin-
gular periodicity values of 34 and 17 Å (typically referred to as ﬁrst- and
second-order cholesterol domain peaks) [35]. Under the speciﬁc
temperature and relative humidity conditions established for these ex-
periments, the second-order, 17 Å cholesterol domain peak was well-
delineated from other, neighboring cholesterol and phospholipid
diffraction peaks and was thus used to quantitate relative cholesterol
domain peak intensity. Routines written in Origin 8.6 (OriginLab Corpo-
ration, Northampton, MA) were used to determine total phospholipid
peak area against which the second-order cholesterol domain peak
was normalized.
2.6. Statistical analyses
Data are presented asmean± S.D. for (N) separate samples or treat-
ment groups. LDL oxidation analyses were conducted in triplicate. Lipid
peroxidation and cholesterol domain peak intensity measurements
were conducted in sextuplicate and triplicate, respectively. Differences
between groups were analyzed using the two-tailed, Student's t-test
(for comparisons between only two groups) or ANOVA followed by
Dunnett or Student–Newman–Keuls multiple comparisons post-hoc
analysis (for comparisons between three or more groups). Alpha error
was set to 0.05 in this study.
3. Results
3.1. Effects of EPA versus other TG-lowering agents on LDL oxidation
We tested the antioxidant effects of EPA and the other TG-lowering
agents in human LDL as it is an important, lipid-enriched particle that
undergoes oxidation in atherosclerosis and other forms of cardiovascu-
lar disease.We ﬁrst examined EPA at 1.0, 2.5, 5.0, and 10.0 μM in human
LDL followed by comparison to other TG-lowering agents (fenoﬁbrate,
niacin, gemﬁbrozil) at 10.0 μM (Fig. 1). EPA was observed to inhibit
lipid oxidation by 19 ± 8% (p b 0.001) at the lowest dose tested
(1.0 μM) and by 92 ± 8% (p b 0.001) at the highest dose tested
(10.0 μM). The IC50 for EPA, calculated from these data, is approximately
3.0 μM. The antioxidant effects of EPAwere not reproduced by the other
TG-lowering agents.
3.2. Comparative effects of EPA and vitamin E on glucose-induced lipid
peroxidation
We also tested the comparative effects of EPA and vitamin E (each at
a 1:30 drug-to-phospholipid mole ratio) on glucose-induced lipid per-
oxidation. As shown in Fig. 2, glucose signiﬁcantly increased LOOH for-
mation in a time-dependent manner as compared to vehicle treatment
alone. EPA inhibited the peroxidative effects of glucose by 85% and 91%
at 72 and 96 hr, respectively,whichwas highly signiﬁcant (p b 0.001) as
compared to glucose treatment alone. By contrast, vitamin E had no sig-
niﬁcant effect on lipid peroxidation under identical conditions.3.3. Separate and combined effects of EPA and ATM on glucose-induced
membrane lipid peroxidation
The activemetabolite of atorvastatin or ATM has been shown in pre-
vious studies to have potent antioxidant properties, as observed in
human low-density lipoprotein as well as model liposomes [36,37]. In
this study, we re-examined the antioxidant effects of ATM, separately
and in combination with EPA (each at 1.0 μM), in membrane lipid
vesicles treated with glucose at 200 mg/dL and exposed to oxidative
conditions for 96 hr (Fig. 3). Both EPA and ATM were observed to
have separate and potent antioxidant effects under these conditions;
however, their combination was even more effective, inhibiting LOOH
formation by N60% (p b 0.001) as compared to either treatment alone.
3.4. Effects of EPA versus other TG-lowering agents on glucose-induced
lipid peroxidation
Using glucose-treated lipid vesicle preparations, we tested the anti-
oxidant effects of EPA at 1.0, 2.5, 5.0, and 10.0 μM following exposure to
oxidative conditions for 48 hr and in comparison to the fenoﬁbrate, ni-
acin, and gemﬁbrozil, each at 10.0 μM(Fig. 4). As observed in similar LDL
experiments, EPAwas shown to inhibit lipid oxidation in a highly signif-
icant and dose-dependent manner. At the lowest dose tested (1.0 μM),
EPA reduced LOOH levels by 28 ± 8% (p b 0.001) as compared to
vehicle-treated controls; at the highest dose tested (10.0 μM), EPA
inhibited lipid oxidation by 86 ± 6% (p b 0.001). The IC50 for EPA was
calculated to be approximately 3.5 μM. The antioxidant effects of EPA
were not reproduced by the other TG-lowering agents in this system.
3.5. Effects of EPA, vitamin E, and other TG-lowering agents on glucose- and
peroxidation-induced changes in membrane lipid structural organization
Lipid peroxidation is highly disruptive to the structural organization
of biological membranes and has been shown, in previous studies, to
contribute directly to the formation of cholesterol crystalline domains
[4,35]. We have also reported that glucose promotes similar changes
in membrane structural organization by increasing lipid peroxidation
[3]. In this study, we used small angle x-ray diffraction to characterize
the structural properties of model membranes treated with glucose
and prepared in the absence or presence of the various test agents
(each at 1:30 drug-to-phospholipid mole ratio), before and after expo-
sure to oxidative conditions (Fig. 5). At the start of this experiment,
EPA, vitamin E and other TG-lowering agents were observed to have
no appreciable effect on membrane structure as compared to control
samples. Scattering data collected from each membrane preparation
yielded up to four diffraction orders having an average unit cell period-
icity (d-space) of 51.5 Å, and consistent with a homogenously-
distributed, lipid bilayer phase. Following exposure to oxidative condi-
tions for 72 hr, additional peaks, with an average d-space value of
34 Å and consistent with a cholesterol crystalline domain phase, were
observed in control and vitamin E-treated membrane samples. At
96 hr, cholesterol domains peaks were observed in all experimental
samples; however, these peaks were disproportionately greater in con-
trol, vitamin E, ﬁbrate, or niacin-treated samples as compared to those
treated with EPA.
Quantitative assessment of cholesterol domain peak intensity
(expressed as the quotient of cholesterol- to total phospholipid-peak
area) indicated that vitamin E and other TG-lowering agents had no sig-
niﬁcant effect on cholesterol domain formation as compared to control
at any experimental time point (Fig. 6). In contrast, EPA inhibited rela-
tive cholesterol domain peak intensity by more than 99% at the 96 hr
time point, as compared to either vehicle or vitamin E treatments. This
inhibitory effect was preserved at EPA concentrations as low as 1:120
drug-to-phospholipid mole ratio, which is equivalent to 10 μM in aque-
ous suspension (data not shown).
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Fig. 6. Quantitative assessment of the comparative effects of vitamin E (Vit E), EPA,
Fenoﬁb, Niacin, and Gemﬁb on cholesterol domain formation in model membranes sub-
jected to glucose-induced lipid peroxidation for 96 hr as shown in Fig. 5. Relative choles-
terol peak intensity values were derived by integrating the second-order cholesterol
domain peak and normalizing to total phospholipid peak area associatedwith a given dif-
fraction pattern. Values aremean± S.D. (N= 3). *p b 0.01 versus vehicle-treated control;
†p b 0.01 versus all other treatments (Student–Newman–Keulsmultiple comparisons test;
overall ANOVA: p= 0.0014, F = 8.229).
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The essentialﬁnding from this study is that EPA, at pharmacologically-
relevant treatment levels [38], signiﬁcantly inhibited glucose-induced
lipid peroxidation and cholesterol crystalline domain formation in
model membrane lipid vesicles. EPA also potently inhibited lipid
oxidation in isolated human LDL. These antioxidant effects are attributed
to the ability of EPA to quench reactive oxygen species (ROS) associated
with the phospholipid membrane, thereby preserving normal lipid
structure and organization. Following intercalation into the membrane
lipid bilayer, the conjugated double bonds associated with EPA facilitate
electron stabilization mechanisms that interfere with free radical propa-
gation (Fig. 7). The effects of EPA could not be reproduced with vitamin
E or other FDA-approved, TG–lowering agents. These ﬁndings indicate a
preferred intercalation of the EPA molecule into the membrane where it
can trap free radicals. The absence of activity for vitamin E under these
conditions is attributed to its limited lipophilicity and scavenging poten-
tial, as previously observed in membranes enriched with cholesterol
[35]. Vitamin E was also unable to interfere with cholesterol crystalline
domain development with hyperglycemia.
At high levels, glucose promoted the formation of LOOH, prominent
intermediates of peroxidative reactions, that lead to changes in the or-
ganization of membrane lipid components [39]. The biophysical conse-
quences of lipid peroxidation have been well characterized and include
changes in membrane ﬂuidity, increased membrane permeability, and
changes in membrane protein activity [40–44]. Oxidative modiﬁcation
of PUFAs also causes a marked reduction in membrane d-space
(i.e., bilayer width plus surface hydration) associated with interdigita-
tion of the phospholipid acyl chain terminal methyl segments [3,45].
These alterations in the intermolecular packing characteristics of mem-
brane phospholipids promote the displacement of cholesterol into dis-
crete domains (d-space of 34 Å) within the phospholipid bilayer
environment [4,46]. Cholesterol crystalline domains were previously
shown to be induced in model membranes by increasing membrane
cholesterol to very high levels (N50 mol%) [46]. Similar changes in cho-
lesterol domain formation have been observed in models of atheroscle-
rosis [6,47,48]. We have also observed the formation of these domains
in membranes prepared at constant cholesterol levels but exposed to
glucose and glucose-induced lipid peroxidation [3]. Thus, agents that
slow or block the aggregation of cholesterol into discrete crystallineFig. 5.Representative x-ray diffraction patterns collected frommodel membranes prepared in th
agents (Fenoﬁb, Niacin, Gemﬁb) and subjected to oxidative conditions for 96 hr.Membraneswe
various agents to achieve a total drug-to-phospholipid mole ratio of 1:30. At 0 hr, each sample e
represented by diffraction peaks 1 through 4. At 72 hr, cholesterol crystalline domains, having
(shown in redﬁll),were also observed inmembrane samples treatedwith vehicle (control), vita
all experimental samples; however, these peaks were disproportionately greater in samples tredomains may interfere with mechanisms of atherogenesis associated
with hyperglycemia without otherwise reducing cholesterol levels.
As a reducingmonosaccharide, glucose is susceptible to reaction at its
anomeric carbonwith singlet oxygen or other radical initiators [49]. This
redox reaction can generate glucose radicals or other reactive oxygen
species that have a pro-oxidant effect in biological membranes. Several
reaction mechanisms are responsible for the formation of glycoxidation
and lipoxidation products resulting from the reaction of glucose radicals
with proteins or lipids to form sugar-amine adducts [50,51].
The presence of cholesterol in the membrane also contributes to
rates of LOOH formation, allowing more efﬁcient radical penetration
and propagation through the bilayer. The steroid nucleus of cholesterol
has an ordering effect on adjacent phospholipid molecules, thus reduc-
ing the intermolecular distance between adjacent PUFA chains of the
lipids and facilitating the exchange of free radicals within the hydrocar-
bon core [4]. We previously demonstrated, in similar model membrane
preparations, a cholesterol-dependent increase in LOOH formation,
which was enhanced by glucose treatment [3]. Evidence suggests that
even minor physicochemical modiﬁcations to the cell membrane may
lead to the disruption of caveolae (cholesterol-enriched membrane do-
mains that are critical to many cellular processes) leading to loss in in-
sulin receptor activity and endothelial nitric oxide synthase (eNOS)
function [8,52].
Glucose-mediated oxidative stress contributes to inﬂammatory
pathways associatedwith diabetes and atherosclerosis pathophysiology
[53]. Elevated glucose levels, obesity, and oxidative stress reduce intra-
cellular antioxidant defensemechanismswhile activating inﬂammatory
responses from transcription factors and kinases, such as c-Jun N-
terminal kinase (JNK), protein kinase C (PKC), and inhibitor of kappa B
kinase-β (IKKβ) [54,55]. Some inﬂammatory pathways, such as activa-
tion of IKKβ, have a causative role in the deleterious effects of hypergly-
cemia on endothelial cell function [56]. Hyperglycemia also stimulates
NF-kB, which in turn promotes the overexpression of NADPH, a primary
source of cellular superoxide. Overproduction of superoxide, accompa-
nied by increased nitric oxide generation, leads to formation of the high-
ly reactive peroxynitrite molecule.
The results of our ﬁndings suggest a novel role for EPA in ameliorat-
ing the effects of hyperglycemia through its potent antioxidant proper-
ties. In clinical studies, puriﬁed EPA reduced CAD-related events in
hypercholesterolemic patients receiving statin treatment [14]. EPA
treatment has also been shown to reduce triglycerides and other ath-
erogenic lipids, as well as oxidized LDL levels, as compared to placebo
[18–20]. These antioxidant effects are consistent with our ﬁndings,
which demonstrate EPA to be a potent and direct scavenger of free rad-
icals. ROS and related oxidative damage have been implicated in the
pathogenesis of various human chronic diseases. Due to its multiple
conjugated double bonds, EPA has higher singlet oxygen quenching
ability as compared to vitamin E. EPA is expected to fully and efﬁciently
incorporate into themembrane bilayerwhere its free radical scavenging
properties can provide greatest beneﬁt.
The antioxidant effects of EPA were enhanced in combination with
the activemetabolite of atorvastatin. According to primary pharmacoki-
netic studies, atorvastatin (parent) is extensivelymetabolized by hepat-
ic cytochrome P450 to yield active, hydroxylated metabolites, which
account for approximately 70% of circulatingHMG-CoA reductase inhib-
itory activity. This is in contrast to other statins like pravastatin and
rosuvastatin that are not metabolized into active forms [37]. Beyond
their enzymatic effects on serum LDL-C levels, the active metabolites
of atorvastatin may provide beneﬁt by interfering with oxidative stress
pathways due to the scavenging activity of its phenoxy group [35,57]. Ine presence of glucose, treatedwith vehicle (control), vitamin E, EPA, or other TG-lowering
re reconstituted fromDLPC and cholesterol at a C/Pmole ratio of 0.6:1 and treatedwith the
xhibited a single lipid bilayer phase with an average periodicity (d-space value) of 51.5 Å,
a characteristic d-space value of 34 Å and represented by a set of distinct diffraction peaks
minE, and other TG-lowering agents. At 96hr, cholesterol domains peakswere observed in
ated with vehicle (control), vitamin E, and other TG-lowering agents as compared to EPA.
Fig. 7. Schematic illustration of the proposed antioxidant and membrane structural effects of EPA as determined by biochemical and biophysical analysis in this study. EPA is shown to
intercalate into the membrane lipid bilayer where it interferes with the propagation of free radicals. The conjugated double bonds associated with EPA are believed to facilitate electron
stabilization mechanisms that quench free radical reactions and preserve membrane lipid structural organization.
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markers of protein oxidation and inﬂammation, atorvastatin was found
to signiﬁcantly reduce circulating levels of chlorotyrosine, nitrotyrosine,
and dityrosine, all of which act as surrogate markers for speciﬁc oxida-
tive pathways upregulated in the atheroma. Interestingly, these effects
were observed at a relatively low treatment dose (10 mg, administered
for just 12 weeks) and were more signiﬁcant than reductions in other
inﬂammatory markers, including C-reactive protein [58]. In a larger
study involving 2,341 patients, treatment with a high dose of atorva-
statin (80 mg) for 16 weeks caused a signiﬁcant reduction in levels
of oxidized lipids associated with all apoB100-containing lipid parti-
cles [59].
The ability of EPA to interfere with oxidative stress under conditions
of hyperglycemia has important clinical implications. Levels of oxidized
lipid, measured using monoclonal antibodies against oxLDL, correlate
with the severity of acute coronary syndromes and plaque instability
[60]. In a longitudinal investigation of 634 patients, we found that
patients with baseline levels of TBARS in the highest quartile had signif-
icantly increased relative risk for major vascular events and proce-
dures [61]. The predictive effect of TBARS was observed in a
multivariate model adjusted for inﬂammatory markers (C-reactive pro-
tein, sICAM-1, IL-6) and other risk factors (age, LDL-C, HDL-C, total cho-
lesterol, triglycerides, BMI, and blood pressure). These analyses
indicated that TBARS had an independent effect on major vascular
events and procedures. Similar predictive value was observed for
LOOH in these same subjects [62]. The potent antioxidant effects of
EPAmay account, in part, for the reduction in CV events reported for hy-
percholesterolemic patients receiving combined EPA and statin treat-
ment as observed in JELIS [14]. In contrast to EPA, the other FDA-
approved, TG-lowering agents failed to interfere with oxidative damage
to themembrane or cholesterol crystal domain development. As shown
in Fig. 6, the addition of thedifferent agents (fenoﬁbrate, gemﬁbrozil, ni-
acin) was actually associated with an increase in cholesterol domain
size. The adverse effects of other approved TG-lowering agents on cho-
lesterol crystal formationmay account, in part, for the absence of clinical
beneﬁts in randomized trials despite their ability to reduce TG levels
(HPS2-THRIVE, FIRST, ACCORD, AIM-HIGH, FIELD) [24–28]. Its lipophilic
structure and molecular space dimensions may allow EPA to insert efﬁ-
ciently into lipoprotein particles and cell lipid membranes as comparedto other TG-lowering agents. Additional prospective studies are under-
way to assess the broader clinical beneﬁts of EPA among high-risk CV
patients. One study, the Reduction of Cardiovascular Events with EPA-
Intervention Trial (REDUCE-IT; NCT01492361), is investigating the ef-
fects of icosapent ethyl (ethyl-EPA) on cardiovascular outcomes in
statin-treated, high-risk patients with hypertriglyceridemia.Acknowledgements
This study was conducted with ﬁnancial support from Amarin
Pharma, Inc. Experimental and technical support was provided by
Seth A. Gerard and Samuel C.R. Sherratt.References
[1] J.W. Baynes, Role of oxidative stress in development of complications in diabetes,
Diabetes 40 (1991) 405–412.
[2] A. Stirban, T. Gawlowski, M. Roden, Vascular effects of advanced glycation
endproducts: clinical effects and molecular mechanisms, Mol. Metab. 3 (2013)
94–108.
[3] Y. Self-Medlin, J. Byun, R.F. Jacob, Y. Mizuno, R.P. Mason, Glucose promotes mem-
brane cholesterol crystalline domain formation by lipid peroxidation, Biochim.
Biophys. Acta 1788 (2009) 1398–1403.
[4] R.F. Jacob, R.P. Mason, Lipid peroxidation induces cholesterol domain formation in
model membranes, J. Biol. Chem. 280 (2005) 39380–39387.
[5] R.P. Mason, R.F. Jacob, Membrane microdomains and vascular biology: emerging
role in atherogenesis, Circulation 107 (2003) 2270–2273.
[6] G. Kellner-Weibel, P.G. Yancey, W.G. Jerome, T. Walser, R.P. Mason, M.C. Phillips,
G.H. Rothblat, Crystallization of free cholesterol in model macrophage foam cells,
Arterioscler. Thromb. Vasc. Biol. 19 (1999) 1891–1898.
[7] J.A. Berliner, A.D. Watson, A role for oxidized phospholipids in atherosclerosis, N.
Engl. J. Med. 353 (2005) 9–11.
[8] M. Bertelsen, E.E. Änggård, M.J. Carrier, Oxidative stress impairs insulin internaliza-
tion in endothelial cells in vitro, Diabetologia 44 (2001) 605–613.
[9] N. Lamharzi, C.B. Renard, F. Kramer, S. Pennathur, J.W. Heinecke, A. Chait, K.E.
Bornfeldt, Hyperlipidemia in concert with hyperglycemia stimulates the prolifera-
tion of macrophages in atherosclerotic lesions: potential role of glucose-oxidized
LDL, Diabetes 53 (2004) 3217–3225.
[10] P. Libby, Inﬂammation in atherosclerosis, Nature 420 (2002) 868–874.
[11] M.L. Daviglus, J. Stamler, A.J. Orencia, A.R. Dyer, K. Liu, P. Greenland, M.K. Walsh, D.
Morris, R.B. Shekelle, Fish consumption and the 30-year risk of fatal myocardial in-
farction, N. Engl. J. Med. 336 (1997) 1046–1053.
[12] D. Mozaffarian, J.H. Wu, Omega-3 fatty acids and cardiovascular disease: effects on
risk factors, molecular pathways, and clinical events, J. Am. Coll. Cardiol. 58 (2011)
2047–2067.
509R.P. Mason, R.F. Jacob / Biochimica et Biophysica Acta 1848 (2015) 502–509[13] P.C. Calder, The role of marine omega-3 (n-3) fatty acids in inﬂammatory
processes, atherosclerosis and plaque stability, Mol. Nutr. Food Res. 56 (2012)
1073–1080.
[14] M. Yokoyama, H. Origasa, M. Matsuzaki, Y. Matsuzawa, Y. Saito, Y. Ishikawa, S.
Oikawa, J. Sasaki, H. Hishida, H. Itakura, T. Kita, A. Kitabatake, N. Nakaya, T. Sakata,
K. Shimada, K. Shirato, Effects of eicosapentaenoic acid on major coronary events
in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded end-
point analysis, Lancet 369 (2007) 1090–1098.
[15] T. Mita, H. Watada, T. Ogihara, T. Nomiyama, O. Ogawa, J. Kinoshita, T. Shimizu, T.
Hirose, Y. Tanaka, R. Kawamori, Eicosapentaenoic acid reduces the progression of
carotid intima-media thickness in patients with type 2 diabetes, Atherosclerosis
191 (2007) 162–167.
[16] A. Takaki, S. Umemoto, K. Ono, K. Seki, T. Ryoke, A. Fujii, T. Itagaki, M. Harada, M.
Tanaka, T. Yonezawa, H. Ogawa, M. Matsuzaki, Add-on therapy of EPA reduces oxi-
dative stress and inhibits the progression of aortic stiffness in patients with coronary
artery disease and statin therapy: a randomized controlled study, J. Atheroscler.
Thromb. 18 (2011) 857–866.
[17] J. Sasaki, T. Miwa, M. Odawara, Administration of highly puriﬁed eicosapentaenoic
acid to statin-treated diabetic patients further improves vascular function, Endocr.
J. 59 (2012) 297–304.
[18] C.M. Ballantyne, H.E. Bays, J.J. Kastelein, E. Stein, J.L. Isaacsohn, R.A. Braeckman, P.N.
Soni, Efﬁcacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in
statin-treated patients with persistent high triglycerides (from the ANCHOR
study), Am. J. Cardiol. 110 (2012) 984–992.
[19] H.E. Bays, C.M. Ballantyne, R.A. Braeckman, W.G. Stirtan, P.N. Soni, Icosapent ethyl, a
pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inﬂam-
mation from the MARINE and ANCHOR studies, Am. J. Cardiovasc. Drugs 13
(2013) 37–46.
[20] H.E. Bays, C.M. Ballantyne, J.J. Kastelein, J.L. Isaacsohn, R.A. Braeckman, P.N. Soni,
Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high tri-
glyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-
blINd, 12-week study with an open-label Extension [MARINE] trial), Am. J. Cardiol.
108 (2011) 682–690.
[21] R.A. Braeckman, M.S. Manku, H.E. Bays, W.G. Stirtan, P.N. Soni, Icosapent ethyl, a
pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in pa-
tients with very high triglyceride levels (results from the MARINE study), Prosta-
glandins Leukot. Essent. Fatty Acids 89 (2013) 195–201.
[22] N. Satoh, A. Shimatsu, K. Kotani, N. Sakane, K. Yamada, T. Suganami, H. Kuzuya, Y.
Ogawa, Puriﬁed eicosapentaenoic acid reduces small dense LDL, remnant lipopro-
tein particles, and C-reactive protein in metabolic syndrome, Diabetes Care 30
(2007) 144–146.
[23] N. Satoh-Asahara, A. Shimatsu, Y. Sasaki, H. Nakaoka, A. Himeno, M. Tochiya, S.
Kono, T. Takaya, K. Ono, H. Wada, T. Suganami, K. Hasegawa, Y. Ogawa, Highly pu-
riﬁed eicosapentaenoic acid increases interleukin-10 levels of peripheral blood
monocytes in obese patients with dyslipidemia, Diabetes Care 35 (2012)
2631–2639.
[24] HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER
niacin/laropiprant: trial design, pre-speciﬁed muscle and liver outcomes, and rea-
sons for stopping study treatment, Eur. Heart J. 34 (2013) 1279–1291.
[25] W.E. Boden, J.L. Probstﬁeld, T. Anderson, B.R. Chaitman, P. Desvignes-Nickens, K.
Koprowicz, R. McBride, K. Teo, W. Weintraub, Niacin in patients with low HDL cho-
lesterol levels receiving intensive statin therapy, N. Engl. J. Med. 365 (2011)
2255–2267.
[26] M.H. Davidson, R.S. Rosenson, K.C. Maki, S.J. Nicholls, C.M. Ballantyne, T. Mazzone,
D.M. Carlson, L.A. Williams, M.T. Kelly, H.S. Camp, A. Lele, J.C. Stolzenbach, Effects
of fenoﬁbric acid on carotid intima-media thickness in patients with mixed dyslip-
idemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST),
Arterioscler. Thromb. Vasc. Biol. 34 (2014) 1298–1306.
[27] H.N. Ginsberg, M.B. Elam, L.C. Lovato, J.R. Crouse III, L.A. Leiter, P. Linz, W.T.
Friedewald, J.B. Buse, H.C. Gerstein, J. Probstﬁeld, R.H. Grimm, F. Ismail-Beigi, J.T.
Bigger, D.C. Goff Jr., W.C. Cushman, D.G. Simons-Morton, R.P. Byington, Effects of
combination lipid therapy in type 2 diabetes mellitus, N. Engl. J. Med. 362 (2010)
1563–1574.
[28] A. Keech, R.J. Simes, P. Barter, J. Best, R. Scott, M.R. Taskinen, P. Forder, A. Pillai, T.
Davis, P. Glasziou, P. Drury, Y.A. Kesaniemi, D. Sullivan, D. Hunt, P. Colman, M.
d'Emden, M. Whiting, C. Ehnholm, M. Laakso, Effects of long-term fenoﬁbrate ther-
apy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the
FIELD study): randomised controlled trial, Lancet 366 (2005) 1849–1861.
[29] M. El-Saadani, H. Esterbauer, M. El-Sayed, M. Goher, A.Y. Nassar, G. Jurgens, A spec-
trophotometric assay for lipid peroxides in serum lipoproteins using commercially
available reagent, J. Lipid Res. 30 (1989) 627–630.
[30] I.T. Mak, W.B. Weglicki, Antioxidant properties of calcium channel blocking drugs,
Methods Enzymol. 234 (1994) 620–630.
[31] K. Yagi, Assay for blood plasma or serum, Methods Enzymol. 105 (1984) 328–331.
[32] A.D. Bangham, M.M. Standish, J.C. Watkins, Diffusion of univalent ions across the la-
mellae of swollen phospholipids, J. Mol. Biol. 13 (1965) 238–252.
[33] L. Herbette, J. Marquardt, A. Scarpa, J.K. Blasie, A direct analysis of lamellar x-ray dif-
fraction from hydrated oriented multilayers of fully functional sarcoplasmic reticu-
lum, Biophys. J. 20 (1977) 245–272.
[34] R.P. Mason, G.E. Gonye, D.W. Chester, L.G. Herbette, Partitioning and location of Bay
K 8644, 1,4-dihydropyridine calcium channel agonist, in model and biological mem-
branes, Biophys. J. 55 (1989) 769–778.[35] R.P. Mason, M.F. Walter, C.A. Day, R.F. Jacob, Active metabolite of atorvastatin in-
hibits membrane cholesterol domain formation by an antioxidant mechanism, J.
Biol. Chem. 281 (2006) 9337–9345.
[36] E. Teissier, A. Nohara, G. Chinetti, R. Paumelle, B. Cariou, J.C. Fruchart, R.P. Brandes, A.
Shah, B. Staels, Peroxisome proliferator-activated receptor alpha induces NADPH ox-
idase activity in macrophages, leading to the generation of LDL with PPAR-alpha ac-
tivation properties, Circ. Res. 95 (2004) 1174–1182.
[37] R.P. Mason, M.F. Walter, C.A. Day, R.F. Jacob, Intermolecular differences for HMG-
CoA reductase inhibitors contribute to distinct pharmacologic and pleiotropic ac-
tions, Am. J. Cardiol. 96 (2005) 11F–23F.
[38] R.A. Braeckman, W.G. Stirtan, P.N. Soni, Pharmacokinetics of eicosapentaenoic acid
in plasma and red blood cells after multiple oral dosing with icosapent ethyl in
healthy subjects, Clin. Pharmacol. Drug Dev. 3 (2014) 101–108.
[39] A.W. Girotti, Lipid hydroperoxide generation, turnover, and effector action in biolog-
ical systems, J. Lipid Res. 39 (1998) 1529–1542.
[40] S.N. Chatterjee, S. Agarwal, Liposomes as membrane model for study of lipid perox-
idation, Free Radic. Biol. Med. 4 (1988) 51–72.
[41] D. Borchman, O.P. Lamba, S. Salmassi, M. Lou, M.C. Yappert, The dual effect of oxida-
tion on lipid bilayer structure, Lipids 27 (1992) 261–265.
[42] M. Kunimoto, K. Inoue, S. Nojima, Effect of ferrous ion and ascorbate-induced lipid
peroxidation on liposomal membranes, Biochem. Biophys. Res. Commun. 646
(1981) 169–178.
[43] A. Sevanian, F. Ursini, Lipid peroxidation in membranes and low-density lipopro-
teins: similarities and differences, Free Radic. Biol. Med. 29 (2000) 306–311.
[44] M.P. Mattson, Modiﬁcation of ion homeostasis by lipid peroxidation: roles in neuro-
nal degeneration and adaptive plasticity, Trends Neurosci. 21 (1998) 53–57.
[45] R.P. Mason, M.F. Walter, P.E. Mason, Effect of oxidative stress on membrane struc-
ture: Small angle x-ray diffraction analysis, Free Radic. Biol. Med. 23 (1997)
419–425.
[46] M.J. Ruocco, G.G. Shipley, Interaction of cholesterol with galactocerebroside and
galactocerebroside-phosphatidylcholine bilayer membranes, Biophys. J. 46 (1984)
695–707.
[47] T.N. Tulenko, M. Chen, P.E. Mason, R.P. Mason, Physical effects of cholesterol on ar-
terial smooth muscle membranes: Evidence of immiscible cholesterol domains and
alterations in bilayer width during atherogenesis, J. Lipid Res. 39 (1998) 947–956.
[48] G.S. Abela, K. Aziz, Cholesterol crystals cause mechanical damage to biological mem-
branes: a proposed mechanism of plaque rupture and erosion leading to arterial
thrombosis, Clin. Cardiol. 28 (2005) 413–420.
[49] V. Jakus, N. Rietbrock, Advanced glycation end-products and the progress of diabetic
vascular complications, Physiol. Res. 53 (2004) 131–142.
[50] M. Brownlee, Biochemistry and molecular cell biology of diabetic complications, Na-
ture 414 (2001) 813–820.
[51] S. Pennathur, J.W. Heinecke, Mechanisms for oxidative stress in diabetic cardiovas-
cular disease, Antioxid. Redox Signal. 9 (2007) 955–969.
[52] A.W. Cohen, T.P. Combs, P.E. Scherer, M.P. Lisanti, Role of caveolin and caveolae in
insulin signaling and diabetes, Am. J. Physiol. Endocrinol. Metab. 285 (2003)
E1151–E1160.
[53] A. Ceriello, E. Motz, Is oxidative stress the pathogenic mechanism underlying insulin
resistance, diabetes, and cardiovascular disease? The common soil hypothesis
revisited, Arterioscler. Thromb. Vasc. Biol. 24 (2004) 816–823.
[54] R.E. Lamb, B.J. Goldstein, Modulating an oxidative-inﬂammatory cascade: potential
new treatment strategy for improving glucose metabolism, insulin resistance, and
vascular function, Int. J. Clin. Pract. 62 (2008) 1087–1095.
[55] H. Tilg, A.R. Moschen, Inﬂammatory mechanisms in the regulation of insulin resis-
tance, Mol. Med. 14 (2008) 222–231.
[56] F. Kim, K.A. Tysseling, J. Rice, B. Gallis, L. Haji, C.M. Giachelli, E.W. Raines, M.A.
Corson, M.W. Schwartz, Activation of IKKbeta by glucose is necessary and sufﬁcient
to impair insulin signaling and nitric oxide production in endothelial cells, J. Mol.
Cell. Cardiol. 39 (2005) 327–334.
[57] M. Aviram, M. Rosenblat, C.L. Bisgaier, R.S. Newton, Atorvastatin and gemﬁbrozil
metabolites, but not the parent drugs, are potent antioxidants against lipoprotein
oxidation, Atherosclerosis 138 (1998) 271–280.
[58] M.H. Shishehbor, M.L. Brenna, R.J. Aviles, X. Fu, M.S. Penn, D.L. Sprecher, S.L. Hazen,
Statins promote potent systemic antioxidant effects through speciﬁc inﬂammatory
pathways, Circulation 108 (2003) 426–431.
[59] S. Tsimikas, J.L. Witztum, E.R. Miller, W.J. Sasiela, M. Szarek, A.G. Olsson, G.G.
Schwartz, High-dose atorvastatin reduces total plasma levels of oxidized phos-
pholipids and immune complexes present on apolipoprotein B-100 in patients
with acute coronary syndromes in the MIRACL trial, Circulation 110 (2004)
1406–1412.
[60] S. Ehara, M. Ueda, T. Naruko, K. Haze, A. Itoh, M. Otsuka, R. Komatsu, T. Matsuo, H.
Itabe, T. Takano, Y. Tsukamoto, M. Yoshiyama, K. Takeuchi, J. Yoshikawa, A.E.
Becker, Elevated levels of oxidized low density lipoprotein show a positive relation-
ship with the severity of acute coronary syndromes, Circulation 103 (2001)
1955–1960.
[61] M.F. Walter, R.F. Jacob, B. Jeffers, M.M. Ghadanfar, G.M. Preston, J. Buch, R.P. Mason,
Serum levels of TBARS predict cardiovascular events in patients with stable coro-
nary artery disease: a longitudinal analysis of the PREVENT study, J. Am. Coll.
Cardiol. 44 (2004) 1996–2002.
[62] M.F.Walter, R.F. Jacob, R.E. Bjork, B. Jeffers, J. Buch, Y.Mizuno, R.P. Mason, Circulating
lipid hydroperoxides predict cardiovascular events in patients with stable coronary
artery disease: the PREVENT study, J. Am. Coll. Cardiol. 51 (2008) 1196–1202.
